Experimental CAR-T therapy aims to clear the way for kidney transplants in hard-to-match patients

NCT ID NCT07350837

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a single dose of AZD0120, a CAR-T cell therapy that targets two immune proteins (CD19 and BCMA), in 12 highly sensitized adults with end-stage kidney disease awaiting a transplant. The goal is to safely reduce the antibodies that make finding a compatible donor difficult. The study will monitor side effects and measure how well the therapy lowers these antibodies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0120 (also called GC012F), a CAR-T cell therapy targeting CD19 and BCMA
What this could lead to: If successful, this could help highly sensitized patients receive a kidney transplant by reducing harmful antibodies that currently make transplantation risky or impossible.
What could go wrong: This is a very early, small trial (12 people) focused on safety. The therapy may not effectively lower antibodies, and there are risks of serious side effects like cytokine release syndrome or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGHLY SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT

Contacts and locations

Locations

Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.